Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
‘Personalized medicine’ bij gastro-intestinale kankersoorten
feb 2020 | Maag-darm-leveroncologie